About Eikonizo
Eikonizo is a company based in Cambridge (United States) founded in 2017 by Janice Kranz, Al Schroeder, and William Shaw.. Eikonizo has raised $2.37 million across 6 funding rounds from investors including Novo Nordisk and HHS. The company has 7 employees as of December 31, 2024. Eikonizo offers products and services including HDAC6 Inhibitors. Eikonizo operates in a competitive market with competitors including T3D Therapeutics, Longeveron, Alchemab, Alzheon and AlphaCognition, among others.
- Headquarter Cambridge, United States
- Employees 7 as on 31 Dec, 2024
- Founders Janice Kranz, Al Schroeder, William Shaw
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Eikonizo Therapeutics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$2.37 M (USD)
in 6 rounds
-
Latest Funding Round
-
Investors
Novo Nordisk
& 1 more
-
Employee Count
7
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Eikonizo
Eikonizo offers a comprehensive portfolio of products and services, including HDAC6 Inhibitors. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Small molecules that inhibit HDAC6 to improve transport and reduce aggregates in diseases
Unlock access to complete
Unlock access to complete
Funding Insights of Eikonizo
Eikonizo has successfully raised a total of $2.37M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Last Round
-
First Round
First Round
(27 Mar 2018)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2024 | Amount | Seed - Eikonizo | Valuation |
investors |
|
| Sep, 2020 | Amount | Grant - Eikonizo | Valuation |
investors |
|
| Sep, 2020 | Amount | Grant - Eikonizo | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Eikonizo
Eikonizo has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Novo Nordisk and HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Drugs for diabetes, obesity, hemophilia, and hormone therapy are manufactured.
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Eikonizo
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Eikonizo
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Eikonizo Comparisons
Competitors of Eikonizo
Eikonizo operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as T3D Therapeutics, Longeveron, Alchemab, Alzheon and AlphaCognition, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for neurodegenerative diseases, including Alzheimer's, are developed.
|
|
| domain | founded_year | HQ Location |
Cellular therapies for aging-related and life-threatening conditions are developed.
|
|
| domain | founded_year | HQ Location |
Developer of antibody based therapeutics to treat cancers, neurodegenerative conditions and infectious diseases
|
|
| domain | founded_year | HQ Location |
Oral inhibitors of amyloid aggregation for Alzheimer's treatment are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for brain and spinal cord diseases are developed.
|
|
| domain | founded_year | HQ Location |
Medical foods and drugs for Alzheimer's disease are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Eikonizo
Frequently Asked Questions about Eikonizo
When was Eikonizo founded?
Eikonizo was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Where is Eikonizo located?
Eikonizo is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Who is the current CEO of Eikonizo?
Janice Kranz is the current CEO of Eikonizo. They have also founded this company.
Is Eikonizo a funded company?
Eikonizo is a funded company, having raised a total of $2.37M across 6 funding rounds to date. The company's 1st funding round was a Grant of $299.98K, raised on Mar 27, 2018.
How many employees does Eikonizo have?
As of Dec 31, 2024, the latest employee count at Eikonizo is 7.
What does Eikonizo do?
Eikonizo was founded in 2017 in Cambridge, United States, and focuses on the biotechnology sector. Small molecule therapeutics that penetrate the brain are developed to address neurodegenerative diseases. The lead program targets selective histone deacetylase 6 (HDAC6) inhibitors for conditions such as Alzheimers disease and amyotrophic lateral sclerosis. Operations center on advancing these inhibitors through research and development stages.
Who are the top competitors of Eikonizo?
Eikonizo's top competitors include Alzheon, Longeveron and Alchemab.
What products or services does Eikonizo offer?
Eikonizo offers HDAC6 Inhibitors.
Who are Eikonizo's investors?
Eikonizo has 2 investors. Key investors include Novo Nordisk, and HHS.